Lexicon Pharmaceuticals, Inc. (LXRX)
Q1 2009 Earnings Call
April 28, 2009 11:00 am ET
Executives
Jason Ray - Manager, Corporate Communications and IR
Dr. Arthur Sands - President and CEO
Dr. Philip Brown - SVP, Clinical Development
Jim Tessmer - VP, Finance and Accounting
Analysts
Chad Messer - Piper Jaffray
Presentation
Operator
Welcome to the Lexicon Pharmaceuticals first quarter 2009 Earnings Call. At this time, all participants are in a listen-only mode. There will be a question-and-answer session to follow. Please be advised that this call is being taped at Lexicon's request.
At this time, I would like to introduce your host for today's call, Jason Ray, Manager of Corporate Communications and Investor Relations. Please go ahead, Mr. Ray.
Jason Ray
Good morning and welcome to the Lexicon Pharmaceuticals first quarter 2009 earnings conference call. I am Jason Ray and with me today are; Dr. Arthur Sands, Lexicon's President and Chief Executive Officer; Dr. Philip Brown Lexicon’s Senior Vice President of Clinical Development; and Jim Tessmer, Lexicon's Vice President of Finance and Accounting.
We expect that you have seen a copy of our earnings press release that was distributed this morning. During this call we will review the information provided in the release and then use the remainder of our time to answer your questions.
The call will begin with Dr. Sands, who will discuss our key accomplishments for the quarter. Dr. Brown will then discuss the status of our drug development programs and Mr. Tessmer, will review our financial results for the first quarter and discuss our financial guidance for 2009. We will then open the call to your questions.
If you would like to view the slides for today's call, please access the Lexicon website at www.lexpharma.com. You will see a link on the home page for today's webcast.
Before we begin, I would like to state that we will be making forward-looking statements, including statements relating to Lexicon's research and development of LX1031, LX1032, LX2931, LX4211 and LX7101. This call may also contain forward-looking statements relating to Lexicon's future operating results, financing arrangements, cash and investments, discovery and development of products, strategic alliances and intellectual property.
Various risks may cause Lexicon's actual results to differ materially from those expressed or implied in such forward-looking statements, including uncertainties related to the timing and results of clinical trials and preclinical studies of our drug candidates, are dependence upon strategic alliances and ability to enter into additional collaboration and license agreements, the success and productivity of our drug discovery efforts, our ability to obtain patent protection for our discoveries, limitations imposed by patents owned or controlled by third parties and the requirements of substantial funding to conduct our drug discovery and development activities. For a list and a description of the risks and uncertainties that we face, please see the reports we have filed with the Securities and Exchange Commission.
No comments:
Post a Comment